查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
缺血性中風市場報告：至2030年的趨勢、預測與競爭分析
市場調查報告書
商品編碼
1356896

缺血性中風市場報告：至2030年的趨勢、預測與競爭分析

Ischemic Stroke Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

缺血性腦中風的趨勢與預測

預計到2030年，全球缺血性中風市場將達到 71.8 億美元，2024年至2030年年複合成長率為 7.5%。這個市場的主要促進因素是人們健康意識的提高，全球糖尿病發病率的上升以及菸草使用者數量的增加。由於CT、MRI、頸動脈超音波和腦血管攝影市場的商機，全球缺血性中風市場前景看好。

按區隔分類的缺血性中風

包含按診斷、藥物類別和地區分類的全球缺血性中風的預測。

缺血性中風相關企業名單

市場上的公司根據其提供的產品品質進行競爭。該市場的主要企業致力於擴大製造設施、投資研發、開拓基礎設施以及利用整個價值鏈的整合機會。這些策略使缺血性中風公司能夠滿足不斷成長的需求，確保競爭力，開發創新產品和技術，降低製造成本，並擴大基本客群。本報告介紹的缺血性腦中風企業如下。

  • Abbott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Medtronic

缺血性中風 Sanofi

  • Lucintel預測，在預測期內，抗血小板藥物將繼續成為最大的細分市場，因為它們用作缺血性中風的一線藥物，以防止血栓形成並最大限度地降低後續中風的風險。
  • CT 可能仍然是最大的區隔，因為它的周轉時間短並且能夠詳細查看大腦解剖結構。
  • 由於該地區政府的積極配合措施和持續的技術進步，北美在預測期內仍然是最大的市場。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個細分市場將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球缺血性中風市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球缺血性中風市場趨勢（2018-2023）與預測（2024-2030）
  • 按診斷分類的全球缺血性中風市場
    • CT
    • MRI
    • 頸超音波檢查
    • 腦血管血管造影術
  • 按藥物類別分類的全球缺血性中風市場
    • 組織纖溶酶原活化劑
    • 抗凝血物
    • 抗血小板藥物
    • 抗高血壓

第4章 2018-2030年市場趨勢及預測分析，依地區

  • 全球缺血性中風市場，依地區
  • 北美缺血性中風市場
  • 歐洲缺血性中風市場
  • 亞太地區缺血性中風市場
  • 其他區域性缺血性中風市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球缺血性中風市場成長機會，依診斷
    • 全球缺血性中風市場成長機會，依藥物類別
    • 全球缺血性中風市場成長機會，依地區
  • 全球缺血性中風市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球缺血性中風市場容量擴張
    • 全球缺血性中風市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Abott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips NV
簡介目錄

Ischemic Stroke Trends and Forecast

The future of the global ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets. The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

A more than 150-page report is developed to help in your business decisions.

Ischemic Stroke by Segment

The study includes a forecast for the global ischemic stroke by diagnosis, drug class, and region.

Ischemic Stroke Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • CT
  • MRI
  • Carotid Ultrasounds
  • Cerebral Angiography

Ischemic Stroke Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Tissue Plasminogen Activator
  • Anticoagulant
  • Antiplatelet
  • Antihypertensive

Ischemic Stroke Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Ischemic Stroke Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ischemic stroke companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ischemic stroke companies profiled in this report include-

  • Abbott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Medtronic

Ischemic Stroke Sanofi

  • Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.
  • CT will remain the largest segment because it ensures short turnaround time and ability to see the brain anatomy in detail.
  • North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Features of the Global Ischemic Stroke Market

  • Market Size Estimates: Ischemic stroke market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Ischemic stroke market size by diagnosis, drug class, and region. in terms of value ($B).
  • Regional Analysis: Ischemic stroke market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different diagnosis, drug class, and region.s for the ischemic stroke market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ischemic stroke market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the ischemic stroke market size?

Answer: The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030.

Q.2. What is the growth forecast for ischemic stroke market?

Answer: The global ischemic stroke market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the ischemic stroke market?

Answer: The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

Q.4. What are the major segments for ischemic stroke market?

Answer: The future of the ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets.

Q.5. Who are the key Ischemic Stroke Market companies?

Answer: Some of the key ischemic stroke companies are as follows:

  • Abbott Laboratories
  • Bayer
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Cordis Corporation
  • Covidien
  • GE Healthcare
  • Genentech
  • Johnson & Johnson
  • Koninklijke Philips N.V.

Q.6. Which ischemic stroke market segment will be the largest in future?

Answer: Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.

Q.7. In ischemic stroke market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ischemic stroke market by diagnosis (CT, MRI, carotid ultrasounds, and cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ischemic Stroke Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Ischemic Stroke Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Ischemic Stroke Market by Diagnosis
    • 3.3.1: CT
    • 3.3.2: MRI
    • 3.3.3: Carotid Ultrasounds
    • 3.3.4: Cerebral Angiography
  • 3.4: Global Ischemic Stroke Market by Drug Class
    • 3.4.1: Tissue Plasminogen Activator
    • 3.4.2: Anticoagulant
    • 3.4.3: Antiplatelet
    • 3.4.4: Antihypertensive

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Ischemic Stroke Market by Region
  • 4.2: North American Ischemic Stroke Market
    • 4.2.2: North American Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
  • 4.3: European Ischemic Stroke Market
    • 4.3.1: European Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
    • 4.3.2: European Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
  • 4.4: APAC Ischemic Stroke Market
    • 4.4.1: APAC Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
    • 4.4.2: APAC Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
  • 4.5: ROW Ischemic Stroke Market
    • 4.5.1: ROW Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
    • 4.5.2: ROW Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Ischemic Stroke Market by Diagnosis
    • 6.1.2: Growth Opportunities for the Global Ischemic Stroke Market by Drug Class
    • 6.1.3: Growth Opportunities for the Global Ischemic Stroke Market by Region
  • 6.2: Emerging Trends in the Global Ischemic Stroke Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Ischemic Stroke Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ischemic Stroke Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abott Laboratories
  • 7.2: Bayer
  • 7.3: Boehringer Ingelheim
  • 7.4: Boston Scientific Corporation
  • 7.5: Cordis Corporation
  • 7.6: Covidien
  • 7.7: GE Healthcare
  • 7.8: Genentech
  • 7.9: Johnson & Johnson
  • 7.10: Koninklijke Philips N.V.